Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System

Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases

(2021) Charles Khouri et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation

(2021) Roger S. McIntyre et al.   AMERICAN JOURNAL OF PSYCHIATRY

Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis

(2021) Sheng-Min Wang et al.   Clinical Psychopharmacology and Neuroscience

Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders

(2021) Felicia Ceban et al.   CNS DRUGS

The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database

(2021) Faizan Mazhar et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies

(2020) Wei Zheng et al.   JOURNAL OF AFFECTIVE DISORDERS

Are we repeating mistakes of the past? A review of the evidence for esketamine

(2020) Mark A. Horowitz et al.   BRITISH JOURNAL OF PSYCHIATRY

Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system

(2020) Milo Gatti et al.   European Journal of Preventive Cardiology

Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database

(2020) Natalia Gonzalez Caldito et al.   Multiple Sclerosis Journal

Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

(2020) Chiara Gastaldon et al.   PSYCHOTHERAPY AND PSYCHOSOMATICS

Increased use of ketamine for the treatment of depression: Benefits and concerns

(2020) Kyoung-Sae Na et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis

(2020) Jiaqi Xiong et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Polypharmacy in a hospitalized psychiatric population: risk estimation and damage quantification

(2019) J. Carmona-Huerta et al.   BMC Psychiatry

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study

(2019) Vanina Popova et al.   AMERICAN JOURNAL OF PSYCHIATRY

A Word to the Wise About Intranasal Esketamine

(2019) Alan F. Schatzberg   AMERICAN JOURNAL OF PSYCHIATRY

Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class

(2019) Jean Kim et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

(2019) Douglas B. Johnson et al.   Journal for ImmunoTherapy of Cancer

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)

(2019) Maggie Fedgchin et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression

(2019) Ella J. Daly et al.   JAMA Psychiatry

Time‐to‐onset analysis of amiodarone‐associated thyroid dysfunction

(2019) Sayoko Kinoshita et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3

(2019) Rachel Ochs-Ross et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

Esketamine: A Novel Option for Treatment-Resistant Depression

(2019) Kevin M. Bozymski et al.   ANNALS OF PHARMACOTHERAPY

Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems

(2018) E. Raschi et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study

(2018) Randall L. Morrison et al.   PSYCHOPHARMACOLOGY

A characterization and disproportionality analysis of medication error related adverse events reported to the FAERS database

(2018) Carla Carnovale et al.   Expert Opinion On Drug Safety

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

(2018) Joe-Elie Salem et al.   LANCET ONCOLOGY

Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems

(2017) E. Raschi et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories

(2016) T. Kishimoto et al.   PSYCHOLOGICAL MEDICINE

An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies

(2015) Miguel-Angel Maciá-Martínez et al.   DRUG SAFETY

The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010

(2014) Keith B. Hoffman et al.   DRUG SAFETY

Gender differences in abusers of amphetamine-type stimulants and ketamine in southwestern China

(2012) Yangyang Zhang et al.   ADDICTIVE BEHAVIORS

Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression

(2012) Carlos A. Zarate et al.   BIOLOGICAL PSYCHIATRY

The prevalence and natural history of urinary symptoms among recreational ketamine users

(2012) Adam R. Winstock et al.   BJU INTERNATIONAL